Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (331-340 of 491) with videos related to

Pageof 50
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2012
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor eraPhilippe A Cassier, Elena Fumagalli, Piotr Rutkowski, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
The Lancet. Oncology|July 8, 2024
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort studyDimitris Bertsimas, Georgios Antonios Margonis, Suleeporn Sujichantararat, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2021
Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomogramsDario Callegaro, Francesco Barretta, Carol J Swallow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
Cancer Chemotherapy and Pharmacology|March 17, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancersEnriqueta Felip, Victor Moreno, Daniel Morgensztern, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 25, 2021
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European studyMahmoud Mohammadi, Nikki S IJzerman, Peter Hohenberger, et al.
Cancer|February 27, 2016
External validation of a multi-institutional retroperitoneal sarcoma nomogramChandrajit P Raut, Rosalba Miceli, Dirk C Strauss, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateEvan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.
Pageof 50

Showing results (331-340 of 491) with videos related to

Sort By:
Pageof 50
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2012
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor eraPhilippe A Cassier, Elena Fumagalli, Piotr Rutkowski, et al.
The Oncologist|January 16, 2021
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapySuzanne George, Robin L Jones, Sebastian Bauer, et al.
The Lancet. Oncology|July 8, 2024
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort studyDimitris Bertsimas, Georgios Antonios Margonis, Suleeporn Sujichantararat, et al.
European Journal of Cancer (Oxford, England : 1990)|September 23, 2021
Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomogramsDario Callegaro, Francesco Barretta, Carol J Swallow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
Cancer Chemotherapy and Pharmacology|March 17, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancersEnriqueta Felip, Victor Moreno, Daniel Morgensztern, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 25, 2021
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European studyMahmoud Mohammadi, Nikki S IJzerman, Peter Hohenberger, et al.
Cancer|February 27, 2016
External validation of a multi-institutional retroperitoneal sarcoma nomogramChandrajit P Raut, Rosalba Miceli, Dirk C Strauss, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2025
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year updateEvan J Lipson, F Stephen Hodi, Hussein Tawbi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.
Pageof 50